Compositions and methods for treating alzheimer's disease
US-2024376452-A1 · Nov 14, 2024 · US
Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1
US9155754B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9155754-B2 |
| Application number | US-201013318713-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 6, 2010 |
| Priority date | May 6, 2009 |
| Publication date | Oct 13, 2015 |
| Grant date | Oct 13, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Lipid transport and metabolism gene, in particular, by targeting natural antisense polynucleotides of a Lipid transport and metabolism gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of a Lipid transport and metabolism genes.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of upregulating a function of and/or the expression of an ABCA1 polynucleotide having SEQ ID NO: 1 in patient cells or tissues in vivo or in sum comprising: contacting said cells or tissues with at least one modified single stranded antisense compound of 12 to 30 nucleotides in length that targets and specifically hybridizes to a complementary region of a natural antisense polynucleotide of the ABCA1 polynucleotide having SEQ ID NO: 8 or 9; thereby u…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9155754B2 cover?
- The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Lipid transport and metabolism gene, in particular, by targeting natural antisense polynucleotides of a Lipid transport and metabolism gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associate…
- Who is the assignee on this patent?
- Collard Joseph, Khorkova Sherman Olga, Curna Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/713. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).